Amgen Inc. (NASDAQ:AMGN) on Saturday released interim Phase 3 trial results showing that Imdelltra, evaluated in combination with AstraZeneca Plc’s (NYSE:AZN) Imfinzi, reduced the risk of death by 58% as a first-line maintenance therapy for extensive-stage small-cell lung cancer.
The DeLLphi-305 study assessed patients whose disease had not worsened after initial chemotherapy and immunotherapy. Researchers presented the findings during a Presidential Symposium at the European Society for Medical Oncology Congress 2026 and published them in The New England Journal of Medicine.
7 months with Imfinzi alone, providing a survival advantage of more than eight months. Approximately 80% of patients who received the combination therapy remained alive at the one-year mark, compared to 53% of individuals treated with monotherapy.
9 months for the monotherapy group. 1% recorded for the control group.
These survival and progression benefits extended across prespecified patient subgroups, including individuals with brain or liver metastases. See More: Top Growth Stocks Manageable Safety Profile and Broader Trial Evidence The safety profile of the combination aligned with the known profiles of the individual drugs.
8% on monotherapy. 6% of patients, presenting predominantly as Grade 1 or 2 events, with zero Grade 4 or greater occurrences.
9 months. In the Phase 3 DeLLphi-304 trial for previously treated patients, the therapy extended median survival by five months over chemotherapy, cutting death risk by 38%.
72 during premarket trading on Monday, according to Benzinga Pro data.
